Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency Enzymology

Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the nonstructural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2′-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Editors ' Picks Source Type: research

Related Links:

County commissioners told the Pittsburgh Business Times and other media outlets last week that they were told to expect targeted mitigation measures by Thursday.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Medical College of Wisconsin president and CEO Dr. John Raymond Sr. called “very troubling” the recent increase in new Covid-19 cases in Wisconsin, but said lagging indicators of the disease’s impact like hospitalizations and deaths are not alarming so far. The number of new diagnoses in Wisconsin jumped in recent days after a lull following the Fourth of July. Wisc onsin posted its four highest days for new cases from July 9 through Sunday ranging from 752 to 929. “Our early indicators…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
An Austin company has created a device that can measure someone's heart beat without any physical contact. The race is on to bring the product to market as the world deals with the coronavirus pandemic. Click through to learn more about their latest partnership.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
A biopharmaceutical company that has been working in collaboration with UAB on an intranasal Covid-19 vaccine candidate said preclinical studies of the candidate had positive results. Altimmune Inc., a Gaithersburg, Maryland-based firm, said the results showed strong neutralizing activity and potent immunity in the respiratory tract. The nasal injection in the respiratory tract may be necessary to block both infection and transmission of the virus and prevent further spread.  Based on the findings,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
The mayor wants to avoid more restrictions on business, but that will depend on whether Covid-19 cases keep rising.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Cases rise by over 230,000 worldwide in 24 hours; 250,000 people in Manila to return to lockdown; Brazil cases near 2m‘Compelling’ evidence air pollution worsens coronavirus – studyGerman study finds low Covid-19 infection rate in schoolsFauci sidelined as Trump ’s White House steps up briefing campaignBereaved urge EU chief to supervise Italian coronavirus inquiry7.57pmBSTThe Trump administration is increasinglyat war with Anthony Fauci, the federal government ’s top public health expert, over the handling of the epidemic, as the US continues to report around 60,000 new cases a day.In what ap...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak World news US news UK news Australia news South Africa Brazil Science Infectious diseases Source Type: news
Conclusion: So far no pharmacological intervention was proven effective and safe to warrant its use in the routine treatment of COVID-19 patients; therefore such patients should ideally be treated in the context of clinical trials. The recommendations herein provided will be revised continuously aiming to capture newly generated evidence.
Source: Revista Brasileira de Terapia Intensiva - Category: Intensive Care Source Type: research
Conclusion: So far no pharmacological intervention was proven effective and safe to warrant its use in the routine treatment of COVID-19 patients; therefore such patients should ideally be treated in the context of clinical trials. The recommendations herein provided will be revised continuously aiming to capture newly generated evidence.
Source: Revista Brasileira de Terapia Intensiva - Category: Intensive Care Source Type: research
Conclusion: So far no pharmacological intervention was proven effective and safe to warrant its use in the routine treatment of COVID-19 patients; therefore such patients should ideally be treated in the context of clinical trials. The recommendations herein provided will be revised continuously aiming to capture newly generated evidence.
Source: Revista Brasileira de Terapia Intensiva - Category: Intensive Care Source Type: research
Conclusion: So far no pharmacological intervention was proven effective and safe to warrant its use in the routine treatment of COVID-19 patients; therefore such patients should ideally be treated in the context of clinical trials. The recommendations herein provided will be revised continuously aiming to capture newly generated evidence.
Source: Revista Brasileira de Terapia Intensiva - Category: Intensive Care Source Type: research
More News: Chemistry | Coronavirus | COVID-19 | Ebola | Hepatitis | Hepatitis C | Lassa Fever | MERS | Middle East Health | Pandemics | Respiratory Medicine | SARS | Study